Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
NCT07335601 · View on ClinicalTrials.gov ↗
Study Summary
A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who developed recurrent MASH. Cohort 2 will consist of subjects who have undergone liver transplant for indications other than MASH cirrhosis who developed de novo MASH.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Resmetirom
Study Locations (15)
California
- University of California San Diego — La Jolla
- University of California Los Angeles Medical Center — Los Angeles
- University of California, San Francisco — San Francisco
Illinois
- Northwestern University — Chicago
- The University of Chicago Medicine — Chicago
New York
- Northwell Health Inc, Center for Liver Disease and Transplantation — Manhasset
- New York Presbyterian Hospital — New York
Texas
- Dallas Methodist — Dallas
- Houston Methodist Hospital — Houston
Colorado
- University of Colorado — Aurora
Minnesota
- Mayo Clinic — Rochester
Tennessee
- Vanderbilt University Medical Center (VUMC) — Nashville
Utah
- Intermountain Medical Center — Murray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-12-29 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07335601
The ClinicalTrials.gov registry entry for NCT07335601 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Madrigal Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with MASH - Metabolic Dysfunction-Associated Steatohepatitis appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07335601 reports 15 study locations spanning 10 distinct geographic areas — top geographies include California, Illinois, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07335601 about?
NCT07335601 is a clinical study titled "Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH". A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MA...
What is the current status of trial NCT07335601?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2025-12-29. Estimated completion is 2027-12.
What conditions does trial NCT07335601 study?
This clinical trial studies the following conditions: MASH - Metabolic Dysfunction-Associated Steatohepatitis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07335601?
The interventions under investigation include: Placebo (DRUG), Resmetirom (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07335601?
This trial is sponsored by Madrigal Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07335601 being conducted?
This trial has 15 study locations across California, Colorado, Illinois, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.